ERBB2 and breast carcinoma: In research, LAFOV PET/CT gives many new opportunities, among others with long-life radionuclides such as Zirconium-89 (89Zr) used in immuno-PET, e.g., with 89Zr-trastuzumab in patients with HER2-positive breast cancer [47].